Novo Nordisk A/S $NVO Shares Sold by Eagle Global Advisors LLC

Eagle Global Advisors LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 26.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 77,198 shares of the company’s stock after selling 28,110 shares during the quarter. Eagle Global Advisors LLC’s holdings in Novo Nordisk A/S were worth $4,284,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. NewSquare Capital LLC grew its position in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $37,000. Maseco LLP acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $39,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S in the third quarter valued at $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.3%

Shares of NVO stock opened at $58.87 on Thursday. The company has a market capitalization of $262.85 billion, a P/E ratio of 17.11 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average is $50.30 and its two-hundred day moving average is $55.11. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

NVO has been the topic of a number of research analyst reports. Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. The Goldman Sachs Group decreased their price objective on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a report on Friday, November 28th. HSBC reaffirmed a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $56.21.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy approval and launch continue to drive upside expectations: analysts and coverage note the FDA approval and early launch of an oral GLP‑1 (“Wegovy pill”) — a catalyst that helped NVO rally recently and supports management’s view that oral pills could capture over a third of the obesity GLP‑1 market by 2030, boosting long‑term growth assumptions. Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
• Positive Sentiment: Management highlights long‑term market opportunity for oral GLP‑1s and sizable addressable base — comments emphasize early 2026 launches and potential for large share gains as pills convert patients using cheaper, unapproved alternatives. This supports upside to revenue forecasts over the coming years. Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030
• Positive Sentiment: R&D focus on differentiated GLP‑1 innovations: the company’s CSO signaled a push for “different flavors” of GLP‑1 and broader pipeline innovation — a constructive signal for sustaining growth beyond the current blockbuster franchises. JPM26: Novo Nordisk’s CSO craving ‘different flavors’ of innovation at conference
• Neutral Sentiment: Investor takeaways and stock momentum pieces note the recent strong run (about +19% month‑over‑month) tied to the oral product — useful context for valuation and sentiment but not new company guidance. Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
• Negative Sentiment: Management warns of 2026 “price pressure” as GLP‑1 supply increases and pricing deals take effect — this implies margin and revenue mix risks in the near term. Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
• Negative Sentiment: Company flags near‑term headwinds in international markets after loss of exclusivity in several countries — a concrete downside to 2026 international revenue expectations. Novo Nordisk flags near-term headwinds in international markets
• Negative Sentiment: Competitor developments trim Novo Nordisk’s near‑term runway — Eli Lilly’s deal (Ventyx) and related market moves have calmed investor concerns about Wegovy competition and supported Lilly shares, which can increase competitive pressure on pricing and market share. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns (NVO)

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.